Dr. Pablo Pelegrin is the principal investigator of the molecular inflammation research group at the Murcia BioHealth Research Institute-Hospital “Virgen de la Arrixaca” in, Murcia, Spain. He has postdoctoral degrees from both the University of Manchester (UK), and from the University of Sheffield (UK). His PhD in developmental immunology was obtained with the University of Murcia. He is an honorary lecturer at the University of Manchester, and Editor of the Inflammasome Journal, published by De Gruyter Open. Dr. Pelegrin has researched the Inflammasome for the past 15 years and is one of the most prolific researchers in this multidisciplinary research area.

• Part I – Fundamentals of Inflammasome Biology 1. Overview of inflammatory processes at cellular level2. Inflammasome formation and triggers3. Cellular signaling, molecular activation and regulation of the NLRP1 inflammasome4. Cellular signaling, molecular activation and regulation of the NLRP3 inflammasome5. Cellular signaling, molecular activation and regulation of the NLRP6 inflammasome6. Cellular signaling, molecular activation and regulation of the NLRC4 inflammasome7. Cellular signaling, molecular activation and regulation of the AIM2 inflammasome8. Cellular signaling, molecular activation and regulation of the Pyrin inflammasome9. Cellular signaling, molecular activation and regulation of the non-canonical inflammasome10. Cellular signaling, molecular activation and regulation of auto-active inflammasomes11. Autophagy and the inflammasome12. Inflammasome effector functions13. Inflammatory caspases14. Structural aspects of inflammasomes15. Evolutive aspects of inflammasomesPart II – inflammasome role in disease processes 16. The inflammasome in cardiovascular diseases 17. Inflammasome implications in metabolic disorders 18. Inflammasome in venous thromboembolic disorders 19. Inflammasomes and neurodegenerative diseases20. Inflammasome implication in diseases of the respiratory system21. Inflammasomes and their regulation in oral disease 22. Inflammasomes in inflammatory bowel disease pathogenesis 23. Inflammasome induced inflammation and fibrosis in liver24. Inflammasomes in sepsis25. The Inflammasome in viral, bacterial and fungal infections26. Autoinflammatory syndromes27. The inflammasome in graft-versus-host disease28. Implication of the inflammasomes in rheumatic diseases29. The inflammasomes in kidney disease30. Inflammasomes and cancer31. Inflammasomes in the pathobiology of degenerative retinopathies.Part III – Inflammasome crosstalk in Cell Death 32. Regulation of pyroptosis by inflammasomes.33. Crosstalk between necroptosis and inflammasome.34. Apoptosis and inflammasome regulation35. Implication of inflammasomes regulating different types of cell death36. Regulation of neutrophil NETosis by inflammasomesPart IV – Therapeutic Opportunities 37. Therapeutic opportunities targeting the inflammasome38. Development of selective inflammasome Inhibitors39. Natural compounds blocking inflammasomes40. Inhibitors targeting inflammasome effectors41. Multi-inflammasome inhibitors

Dr. Pablo Pelegrin is the principal investigator of the molecular inflammation research group at the Murcia BioHealth Research Institute-Hospital “Virgen de la Arrixaca” in, Murcia, Spain. He has postdoctoral degrees from both the University of Manchester (UK), and from the University of Sheffield (UK). His PhD in developmental immunology was obtained with the University of Murcia. He is an honorary lecturer at the University of Manchester, and Editor of the Inflammasome Journal, published by De Gruyter Open. Dr. Pelegrin has researched the Inflammasome for the past 15 years and is one of the most prolific researchers in this multidisciplinary research area.

• Part I – Fundamentals of Inflammasome Biology 1. Overview of inflammatory processes at cellular level2. Inflammasome formation and triggers3. Cellular signaling, molecular activation and regulation of the NLRP1 inflammasome4. Cellular signaling, molecular activation and regulation of the NLRP3 inflammasome5. Cellular signaling, molecular activation and regulation of the NLRP6 inflammasome6. Cellular signaling, molecular activation and regulation of the NLRC4 inflammasome7. Cellular signaling, molecular activation and regulation of the AIM2 inflammasome8. Cellular signaling, molecular activation and regulation of the Pyrin inflammasome9. Cellular signaling, molecular activation and regulation of the non-canonical inflammasome10. Cellular signaling, molecular activation and regulation of auto-active inflammasomes11. Autophagy and the inflammasome12. Inflammasome effector functions13. Inflammatory caspases14. Structural aspects of inflammasomes15. Evolutive aspects of inflammasomesPart II – inflammasome role in disease processes 16. The inflammasome in cardiovascular diseases 17. Inflammasome implications in metabolic disorders 18. Inflammasome in venous thromboembolic disorders 19. Inflammasomes and neurodegenerative diseases20. Inflammasome implication in diseases of the respiratory system21. Inflammasomes and their regulation in oral disease 22. Inflammasomes in inflammatory bowel disease pathogenesis 23. Inflammasome induced inflammation and fibrosis in liver24. Inflammasomes in sepsis25. The Inflammasome in viral, bacterial and fungal infections26. Autoinflammatory syndromes27. The inflammasome in graft-versus-host disease28. Implication of the inflammasomes in rheumatic diseases29. The inflammasomes in kidney disease30. Inflammasomes and cancer31. Inflammasomes in the pathobiology of degenerative retinopathies.Part III – Inflammasome crosstalk in Cell Death 32. Regulation of pyroptosis by inflammasomes.33. Crosstalk between necroptosis and inflammasome.34. Apoptosis and inflammasome regulation35. Implication of inflammasomes regulating different types of cell death36. Regulation of neutrophil NETosis by inflammasomesPart IV – Therapeutic Opportunities 37. Therapeutic opportunities targeting the inflammasome38. Development of selective inflammasome Inhibitors39. Natural compounds blocking inflammasomes40. Inhibitors targeting inflammasome effectors41. Multi-inflammasome inhibitors

Dr. Pablo Pelegrin is the principal investigator of the molecular inflammation research group at the Murcia BioHealth Research Institute-Hospital “Virgen de la Arrixaca” in, Murcia, Spain. He has postdoctoral degrees from both the University of Manchester (UK), and from the University of Sheffield (UK). His PhD in developmental immunology was obtained with the University of Murcia. He is an honorary lecturer at the University of Manchester, and Editor of the Inflammasome Journal, published by De Gruyter Open. Dr. Pelegrin has researched the Inflammasome for the past 15 years and is one of the most prolific researchers in this multidisciplinary research area.

• Part I – Fundamentals of Inflammasome Biology 1. Overview of inflammatory processes at cellular level2. Inflammasome formation and triggers3. Cellular signaling, molecular activation and regulation of the NLRP1 inflammasome4. Cellular signaling, molecular activation and regulation of the NLRP3 inflammasome5. Cellular signaling, molecular activation and regulation of the NLRP6 inflammasome6. Cellular signaling, molecular activation and regulation of the NLRC4 inflammasome7. Cellular signaling, molecular activation and regulation of the AIM2 inflammasome8. Cellular signaling, molecular activation and regulation of the Pyrin inflammasome9. Cellular signaling, molecular activation and regulation of the non-canonical inflammasome10. Cellular signaling, molecular activation and regulation of auto-active inflammasomes11. Autophagy and the inflammasome12. Inflammasome effector functions13. Inflammatory caspases14. Structural aspects of inflammasomes15. Evolutive aspects of inflammasomesPart II – inflammasome role in disease processes 16. The inflammasome in cardiovascular diseases 17. Inflammasome implications in metabolic disorders 18. Inflammasome in venous thromboembolic disorders 19. Inflammasomes and neurodegenerative diseases20. Inflammasome implication in diseases of the respiratory system21. Inflammasomes and their regulation in oral disease 22. Inflammasomes in inflammatory bowel disease pathogenesis 23. Inflammasome induced inflammation and fibrosis in liver24. Inflammasomes in sepsis25. The Inflammasome in viral, bacterial and fungal infections26. Autoinflammatory syndromes27. The inflammasome in graft-versus-host disease28. Implication of the inflammasomes in rheumatic diseases29. The inflammasomes in kidney disease30. Inflammasomes and cancer31. Inflammasomes in the pathobiology of degenerative retinopathies.Part III – Inflammasome crosstalk in Cell Death 32. Regulation of pyroptosis by inflammasomes.33. Crosstalk between necroptosis and inflammasome.34. Apoptosis and inflammasome regulation35. Implication of inflammasomes regulating different types of cell death36. Regulation of neutrophil NETosis by inflammasomesPart IV – Therapeutic Opportunities 37. Therapeutic opportunities targeting the inflammasome38. Development of selective inflammasome Inhibitors39. Natural compounds blocking inflammasomes40. Inhibitors targeting inflammasome effectors41. Multi-inflammasome inhibitors